New Sequence Analysis Tools Have 'Trickle-Down' Benefit for Array Users, Vendors Say | GenomeWeb

By Justin Petrone

As the rise of next-generation sequencing has driven demand for new analytical tools, many software companies that have long served array users have shifted their resources to this rapidly growing segment of the market.

But microarray users haven't been left behind as a result of this trend, according to sources familiar with the industry who told BioArray News that these new NGS analysis tools will have a "trickle-down effect" or "fringe benefit" for array clients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.